Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

HutchMed/AstraZeneca Approved to Launch Partnered MET Inhibitor in China

publication date: Jun 24, 2021

HutchMed and AstraZeneca report their MET tyrosine kinase inhibitor was granted conditional China approval for patients with a rare form of NSCLC. Orpathys (savolitinib) was approved as a second-line treatment for NSCLC with MET exon 14 skipping alterations. For those who are unable to receive chemotherapy, it will be a first-line therapy. Approximately 2-3% of NSCLC patients have MET exon 14 skipping alterations, a targetable mutation in the MET gene. It is the first approval for savolitinib, which HutchMed partnered with AstraZeneca ten years ago. More details....

Stock Symbols: (NSDQ/AIM: HMP) (NYSE: AZM)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.